Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wendling

Showing results (51-60 of 496) with videos related to

Pageof 50
Sort By:
Joint Bone Spine|December 3, 2010
Using targeted therapies alone for rheumatoid arthritisClément Prati, Daniel Wendling
Joint Bone Spine|May 7, 2016
Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy?Daniel Wendling, Clément Prati
Expert Opinion on Pharmacotherapy|June 24, 2004
Anti-TNF-alpha therapy in ankylosing spondylitisDaniel Wendling, Eric Toussirot
Joint Bone Spine|May 30, 2006
Serum tissue factor levels correlate with inflammation in ankylosing spondylitisDaniel Wendling, Evelyne Racadot
Expert Opinion on Pharmacotherapy|August 24, 2007
The use of TNF-alpha blocking agents in rheumatoid arthritis: an updateEric Toussirot, Daniel Wendling
Joint Bone Spine|December 11, 2013
Sirt1 and osteoarthritis. Comments on the paper by Gabay et al.: "Sirt1-deficient mice exhibit an altered cartilage phenotype", Joint Bone Spine 2013Daniel Wendling, Georges Herbein
Joint Bone Spine|October 11, 2015
Remission in axial spondyloarthritis: The ultimate treatment goal?Daniel Wendling, Clément Prati
Rheumatology International|October 15, 2015
Smoking and spondyloarthritis: a bad connectionDaniel Wendling, Clément Prati
Clinical Rheumatology|July 23, 2016
Spondyloarthritis and fibromyalgia: interfering association or differential diagnosis?Daniel Wendling, Clément Prati
The Journal of Rheumatology|August 19, 2007
Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?Daniel Wendling, Eric Toussirot
Pageof 50

Showing results (51-60 of 496) with videos related to

Sort By:
Pageof 50
Joint Bone Spine|December 3, 2010
Using targeted therapies alone for rheumatoid arthritisClément Prati, Daniel Wendling
Joint Bone Spine|May 7, 2016
Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy?Daniel Wendling, Clément Prati
Expert Opinion on Pharmacotherapy|June 24, 2004
Anti-TNF-alpha therapy in ankylosing spondylitisDaniel Wendling, Eric Toussirot
Joint Bone Spine|May 30, 2006
Serum tissue factor levels correlate with inflammation in ankylosing spondylitisDaniel Wendling, Evelyne Racadot
Expert Opinion on Pharmacotherapy|August 24, 2007
The use of TNF-alpha blocking agents in rheumatoid arthritis: an updateEric Toussirot, Daniel Wendling
Joint Bone Spine|December 11, 2013
Sirt1 and osteoarthritis. Comments on the paper by Gabay et al.: "Sirt1-deficient mice exhibit an altered cartilage phenotype", Joint Bone Spine 2013Daniel Wendling, Georges Herbein
Joint Bone Spine|October 11, 2015
Remission in axial spondyloarthritis: The ultimate treatment goal?Daniel Wendling, Clément Prati
Rheumatology International|October 15, 2015
Smoking and spondyloarthritis: a bad connectionDaniel Wendling, Clément Prati
Clinical Rheumatology|July 23, 2016
Spondyloarthritis and fibromyalgia: interfering association or differential diagnosis?Daniel Wendling, Clément Prati
The Journal of Rheumatology|August 19, 2007
Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?Daniel Wendling, Eric Toussirot
Pageof 50